Publication

Pharmacy Benefit Managers Now on the Hook to Provide Greater Transparency on Fee Structures

Nov 13, 2026

On November 2, 2026, the Department of Labor (“DOL”) published final regulations (the “Final Rule”) under ERISA Section 408(b)(2) imposing extensive new disclosure requirements on pharmacy benefit managers (“PBM”) and certain affiliates that serve large self-insured group health plans.

The Final Rule implements the transparency reforms of the Consolidated Appropriations Act, 2026 (“CAA 2026”) and responds to Executive Order 14273, Lowering Drug Prices by Once Again Putting Americans First, which directed the DOL to improve plans’ transparency into PBMs’ compensation. The Final Rule harmonizes coverage, reporting and terminology with CAA 2026, but does not fully consolidate statutory and regulatory obligations or align implementation dates.

Effective dates: The Final Rule applies to plan years beginning on or after July 1, 2027 (January 1, 2028 for calendar-year plans). The CAA 2026 rebate and reporting requirements apply to plan years beginning on or after August 3, 2028 (January 1, 2029 for calendar-year plans).

  1. Who Must Comply with the Disclosure Requirements?

The Final Rule applies to “covered plans” and “covered service providers.” A “covered plan” is a self-insured ERISA group health plan offered by a “specified large employer” or a “specified large plan” (generally, employers with 100 or more employees or plans with 100 or more participants in the prior year), excluding fully insured plans and plans sponsored by or affiliated with drug manufacturers, distributors, wholesalers, PBMs or rebate aggregators. A “covered service provider” is a service provider that contracts with a covered plan and reasonably expects to receive $1,000 or more in direct or indirect compensation in connection with:

  • Providing PBM services, meaning any services needed to manage or administer the plan’s prescription drug benefit (such as rebate negotiation, formulary and pharmacy network management, utilization management and claims processing), whether or not the provider calls itself a “pharmacy benefit manager”; or
  • Providing advice, recommendations or referrals regarding PBM services, but only when provided by a PBM or its affiliate.

For ease of reference, we refer to a covered plan as a “plan,” a covered service provider as a “PBM” and their contract or arrangement as a “PBM agreement,” recognizing that other entities (such as third-party administrators providing PBM services) may also be covered service providers.

Plans outside the Final Rule (including smaller and fully insured plans) remain subject to ERISA Section 408(b)(2)(B), which CAA 2026 amended effective February 3, 2026 to clearly cover PBMs and TPAs.

  1. What Disclosures Are Required?

The Final Rule requires initial disclosures, semiannual (or, at the plan’s request, quarterly) disclosures and on-request disclosures. All disclosures must be clear, concise, accurate, and specific enough for the plan fiduciary to evaluate reasonableness. Generic industry terms, jargon or legalese are insufficient unless they reference publicly available, objectively determinable definitions. Compensation must be stated as a dollar amount, and good-faith estimates are permitted only when the actual amount is not reasonably ascertainable. The PBM must provide the disclosures in a machine-readable file upon request and may not restrict the plan fiduciary’s use of the disclosures, but may require confidentiality agreements with third-party recipients.

  1. Initial Disclosures

PBMs must furnish written disclosures to the plan fiduciary reasonably in advance of entering into, extending or renewing a PBM agreement; for extensions and renewals, the Final Rule treats 90 calendar days in advance as reasonable unless the parties agree to a longer period. Compensation amounts must be expressed on a semiannual basis (or quarterly, at the plan’s request). The initial disclosure must include:

  • Description of services.
  • Description of the PBM’s Compensation.
    • Direct compensation – compensation received from the plan or plan sponsor.
    • Manufacturer payments – rebates, fees, discounts and other remuneration from drug manufacturers.
    • Spread compensation – the difference between the negotiated rate the plan pays the PBM and the rate the PBM pays the pharmacy.
    • Pharmacy recoupment or copay clawback compensation – the difference between the participant’s copayment or coinsurance and the PBM’s reimbursement to the pharmacy.
    • Price protection agreements – negotiated manufacturer rebates that protect the PBM from price increases or inflation.
    • Termination compensation – amounts received on termination of the PBM agreement.
    • Other compensation – any other compensation connected to the PBM agreement.
    • Formulary placement incentives – rebates, fees, or price concessions paid by manufacturers in exchange for placing or favoring a drug on the plan’s formulary.
    • Drug pricing methodology – net cost of each formulary drug to the plan by pharmacy channel.
  • Statement of the PBM’s fiduciary status.
  • Statement of audit right.
  1. Semiannual (or Quarterly) Disclosures

Within 30 days after each six-month period measured from the PBM agreement date (or, at the plan’s request, each quarter), the PBM must report the actual compensation received during the preceding period in each initial disclosure category. If any category materially exceeds the initial estimate, the PBM must explain the amount of and reason for the overage. “Material” means five percent or any lower amount to which the parties agree.

  1. On-Request Disclosures

On written request, the PBM must furnish a plan fiduciary with any other information relating to the PBM agreement that the plan needs to comply with ERISA reporting and disclosure requirements (e.g., Form 5500 filings or Prescription Drug Data Collection reporting).

  1. How Does the Plan Verify the Disclosures?

The PBM agreement must allow at least annual audits of the disclosures. The plan alone selects the auditor, and the PBM may not impose restrictive conditions on the audit. Absent extraordinary circumstances, the PBM must, within 60 days of request, give the auditor access to all records, claims and transaction-level data and other information reasonably necessary to confirm the accuracy of the disclosures, including contracts with retail pharmacies and drug manufacturers. The plan pays the auditor; the PBM bears the cost of producing the information.

  1. What Are the Consequences of Noncompliance?

If the plan fiduciary does not receive and review the required disclosures, the PBM agreement is not a “reasonable” contract under ERISA Section 408(b)(2), potentially resulting in a prohibited transaction for both the plan fiduciary and the PBM. The Final Rule includes an administrative class exemption for plan fiduciaries who did not know of the PBM’s failure and reasonably believed the requirements were met. Upon discovery, the plan fiduciary must request correction in writing, notify the DOL if the PBM does not comply within 90 calendar days, and document a prudent decision whether to terminate or continue the PBM agreement. Importantly, the exemption protects only the plan fiduciary; the PBM remains exposed to prohibited transaction liability and civil penalties.

  1. What Are the Next Steps for Plan Sponsors?

Although PBMs and their affiliates bear most of the disclosure burden, plan fiduciaries must review the disclosures and evaluate the reasonableness of their PBM agreements. Plan sponsors should begin preparing now by considering the following steps:

  1. Identify all covered service providers. Determine whether the plan is covered by the Final Rule and, if so, identify the plan’s covered service providers.
  2. Review existing PBM contracts. Review and revise existing PBM agreements to comply with the Final Rule, including provisions addressing disclosure obligations, semiannual or quarterly reporting elections, notice of formulary changes, audit and termination rights and confidentiality requirements.
  3. Build a disclosure review process. Engage consultants, auditors or internal subject matter experts to analyze the PBM compensation data, review each periodic disclosure and escalate material overages for fiduciary action.
  4. Coordinate with legal counsel and benefits consultants. Work with ERISA counsel and benefits consultants on a compliance timeline and fiduciary procedures, including documenting any decision to continue or terminate a noncompliant PBM.

About Snell & Wilmer

Founded in 1938, Snell & Wilmer is a full-service business law firm with more than 550 attorneys practicing in 18 locations throughout the United States and in Mexico, including Phoenix and Tucson, Arizona; Los Angeles, Orange County, Palo Alto and San Diego, California; Denver, Colorado; Washington, D.C.; Boise, Idaho; Las Vegas and Reno-Tahoe, Nevada; Albuquerque, New Mexico; Portland, Oregon; Dallas, Texas; Salt Lake City, Utah; Seattle, Washington; and Los Cabos and Mexico City in Mexico. The firm represents clients ranging from large, publicly traded corporations to small businesses, individuals and entrepreneurs. For more information, visit swlaw.com.

©2026 Snell & Wilmer L.L.P. All rights reserved. The purpose of this publication is to provide readers with information on current topics of general interest and nothing herein shall be construed to create, offer, or memorialize the existence of an attorney-client relationship. The content should not be considered legal advice or opinion, because it may not apply to the specific facts of a particular matter. As guidance in areas is constantly changing and evolving, you should consider checking for updated guidance, or consult with legal counsel, before making any decisions.
Media Contact

Olivia Nguyen-Quang

Director of Communications & Marketing
media@swlaw.com 714.427.7490